Introduction: The new crown epidemic can only be controlled by vaccines at present, and Western countries are already undergoing vaccination. For example, in the United States, the United Kingdom, Australia and other countries, the vaccine they received was developed by Pfizer . After vaccination, some people have experienced adverse reactions.
Taiwan's vaccine development progress is behind, with 300 million subsidies flying
According to Taiwan media reports, Taiwan's vaccine has always lagged behind in the process of research and development. Taiwan’s three pharmaceutical factories that develop new crown vaccines, Guoguang Biotechnology is ahead of the other two vaccine companies, and is faster than the other two. However, because the antibody price does not meet expectations, it has never been able to pass the review. In addition, Lianya and Gaotou are still under the observation period because the patients undergoing the trial are still in the observation period and do not have enough data. The results may not be disclosed until January next year.
Some people say that by the end of the year, no vaccine may be able to enter the second phase of clinical trials, and by then, the R&D subsidy of up to 300 million yuan will not be obtained from the DRC. Previously, Taiwan’s Minister of Health and Welfare Chen Shih-chung’s plan to review and approve the launch of local vaccines in June next year may be disappointed. As early as August, Guoguang Biotechnology progressed quite fast, and the first to obtain the results of the first phase of clinical trials, and the outside world is quite optimistic about it. However, because Guoguang Biotechnology Antibody Performance is poor, it is impossible to pass the psychological expectations of the consortium's legal person's medical and drug inspection center, it is delayed in the second phase of clinical trials.
Taiwan may not be able to obtain the vaccine on time
Lianya vaccine has the same problem compared with Guoguang vaccine. Although high-end vaccines started late, high-end vaccines have the "noble" status of NIH technology transformation in the US National Health Hospital. The outside world unanimously believes that even if they start slowly, they will catch up in the future.
Guoguang spokesperson did not respond to the delay in the second phase of the vaccine produced because the antibody price was not as high as expected. He said that it is indeed quite difficult to get a subsidy of 300 million yuan this year, but Guoguang’s goal is not to obtain full subsidies. As long as the Food and Drug Administration can approve it, it will start the next phase of trials and develop the vaccine as soon as possible.
Because Taiwan's vaccine development progress is quite backward, it may not be able to achieve Taiwan's previous promise to vaccinate the people in June next year, and it may not be approved until August. The specific time to approve the use depends on the progress of these pharmaceutical companies in Taiwan and depends on the specific progress. It seems that the Taiwanese authorities will not be able to vaccinate the people in a short period of time.
article丨Ye Feng Review丨Chencheng
This article was created by "New Observation of Taiwan Strait". The pictures are from the Internet. If there is any infringement, please contact us to inform
. Some messages are reference: Taiwan Strait Network
